Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik S Knudsen

Showing results (1-10 of 181) with videos related to

Pageof 19
Sort By:
Oncotarget|August 21, 2018
The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle controlErik S Knudsen, Eldad Zacksenhaus
Experimental Biology and Medicine (Maywood, N.J.)|July 4, 2006
Retinoblastoma tumor suppressor: where cancer meets the cell cycleErik S Knudsen, Karen E Knudsen
Nucleic Acids Research|March 16, 2005
Differential role of RB in response to UV and IR damageEmily E Bosco, Erik S Knudsen
Cell Cycle (Georgetown, Tex.)|April 20, 2011
RB pathway and therapeutic sensitivity: new insights in breast cancer and Tamoxifen therapyAgnieszka K Witkiewicz, Erik S Knudsen
Breast Cancer Research : BCR|September 17, 2014
Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventionsAgnieszka K Witkiewicz, Erik S Knudsen
Trends in Cancer|March 18, 2017
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination StrategiesErik S Knudsen, Agnieszka K Witkiewicz
Oncotarget|August 27, 2016
Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancerErik S Knudsen, Agnieszka K Witkiewicz
Cell Cycle (Georgetown, Tex.)|March 16, 2007
RB in breast cancer: at the crossroads of tumorigenesis and treatmentEmily E Bosco, Erik S Knudsen
Nature Reviews. Cancer|January 15, 2009
Tailoring to RB: tumour suppressor status and therapeutic responseErik S Knudsen, Karen E Knudsen
Aging|September 2, 2017
The transcriptome of CDK4/6 inhibitionErik S Knudsen, Agnieszka K Witkiewicz
Pageof 19

Showing results (1-10 of 181) with videos related to

Sort By:
Pageof 19
Oncotarget|August 21, 2018
The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle controlErik S Knudsen, Eldad Zacksenhaus
Experimental Biology and Medicine (Maywood, N.J.)|July 4, 2006
Retinoblastoma tumor suppressor: where cancer meets the cell cycleErik S Knudsen, Karen E Knudsen
Nucleic Acids Research|March 16, 2005
Differential role of RB in response to UV and IR damageEmily E Bosco, Erik S Knudsen
Cell Cycle (Georgetown, Tex.)|April 20, 2011
RB pathway and therapeutic sensitivity: new insights in breast cancer and Tamoxifen therapyAgnieszka K Witkiewicz, Erik S Knudsen
Breast Cancer Research : BCR|September 17, 2014
Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventionsAgnieszka K Witkiewicz, Erik S Knudsen
Trends in Cancer|March 18, 2017
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination StrategiesErik S Knudsen, Agnieszka K Witkiewicz
Oncotarget|August 27, 2016
Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancerErik S Knudsen, Agnieszka K Witkiewicz
Cell Cycle (Georgetown, Tex.)|March 16, 2007
RB in breast cancer: at the crossroads of tumorigenesis and treatmentEmily E Bosco, Erik S Knudsen
Nature Reviews. Cancer|January 15, 2009
Tailoring to RB: tumour suppressor status and therapeutic responseErik S Knudsen, Karen E Knudsen
Aging|September 2, 2017
The transcriptome of CDK4/6 inhibitionErik S Knudsen, Agnieszka K Witkiewicz
Pageof 19